We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Supreme Court Says No to Hearing Biogen’s Attempt to Reinstate Tecfidera Patent
Supreme Court Says No to Hearing Biogen’s Attempt to Reinstate Tecfidera Patent
The U.S. Supreme Court has refused to hear Biogen’s argument that its patent on the blockbuster multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) should be reinstated as part of the company’s ongoing fight with Mylan Pharmaceuticals, which has for two years marketed a generic version of the drug.